© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
June 11, 2021
In this video, Ranjith Ramasamy, MD, explains that although testosterone therapy comes with risks, “these risks appear to be very, very small.”
June 10, 2021
Many factors play into decision-making process when weighing agents.
May 27, 2021
The new treatment is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate.
May 26, 2021
In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.
May 25, 2021
The TAVT-45 formulation of abiraterone acetate consists of granules for oral suspension.
May 20, 2021
Ranjith Ramasamy, MD, explains how the oral testosterone capsule Jatenzo works and touches on key findings from a recent study of the treatment.
May 17, 2021
In contrast, following development of metastatic castration-resistant prostate cancer, time to castration resistance did not influence overall survival.
May 04, 2021
The approval was based on data from the phase 3 ARCHES trial.
April 21, 2021
Hamilton discusses findings from a recent study published in European Urology.
April 20, 2021
The novel combination of apalutamide plus abiraterone and prednisone had previously met the primary end point of radiographic progression-free survival in the phase 3 ACIS trial.